TLR3 and neoplasm: Considering expression of TLR3 on both tumor and immune cells, NSCLC cases that expressed TLR3-s but not TLR3-t had a significantly worse prognosis compared with all other patients (p = 0.0093; Wilcoxon test) (Fig. 2D).